Recently Adopted and Issued Accounting Guidance (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Changes and Error Corrections [Abstract]

Summary of Adoption of New Accounting Pronouncements

Select condensed consolidated balance sheet line items, which reflect the adoption of ASC 606, are as follows (in thousands):

	December 31, 2017
	As Reported		Impact of Adoption			As Adjusted
Other current assets	$	4,241	$	912		$	5,153
Other assets	689		202			891
Total Assets	$	343,340	$	1,114		$	344,454
Pharma contract liability	$	—	$	1,406		$	1,406
Long-term pharma contract liability	—		283			283
Deferred income tax liability, net	6,307		381			6,688
Stockholders' Equity	172,918		(956		)	171,962
Total Liabilities and Stockholders' Equity	$	343,340	$	1,114		$	344,454

Select unaudited condensed consolidated statement of operations line items, which reflect the adoption of ASC 606, are as follows (in thousands):

	For the Three Months Ended June 30, 2017									For the Six Months Ended June 30, 2017
	As Reported			Impact of Adoption			As Adjusted			As Reported			Impact of Adoption			As Adjusted
Net Revenue
Clinical Services	$	59,791		$	(4,244	)	$	55,547		$	116,482		$	(8,027	)	$	108,455
Pharma Services	6,299			418			6,717			11,285			(47		)	11,238
Total Revenue	$	66,090		$	(3,826	)	$	62,264		$	127,767		$	(8,074	)	$	119,693
Gross Profit	$	31,178		$	(3,826	)	$	27,352		$	58,374		$	(8,073	)	$	50,301
Total operating expenses (1)	$	29,864		$	(4,353	)	$	25,511		$	57,175		$	(8,137	)	$	49,038
Income from Operations	1,314			527			1,841			1,199			64			1,263
Interest expense	1,411			—			1,411			2,775			—			2,775
Income tax (benefit) expense	(54		)	1			(53		)	(879		)	47			(832		)
Net Income (Loss)	$	(43	)	$	526		$	483		$	(697	)	$	17		(680		)